INSPYR THERAPEUTICS

Inspyr Therapeutics is a development stage company, focuses on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, and kidney cancer. The company involves in the discovery and development of pro-drug cancer therapeutics. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its pro-drug development candidates include G-202, which is in Phase I clinical trails and targets the blood vessels of various solid tumors; and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for the treatment of prostate cancer. The company was founded in 2003 and is based in San Antonio, Texas.